MicroRNA therapeutics in neurological disease

Current Pharmaceutical Design

Volumn 20, Issue 38, 2014, Pages 6022-6027

  Greenberg, David S ^a   Soreq, Hermona ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

MicroRNA; Neurodegeneration; Neurological disease; Therapy

Indexed keywords

ANTAGOMIR; MICRORNA; MICRORNA 132;

ARTICLE; BLOOD BRAIN BARRIER; CHOLINERGIC SYSTEM; CHOLINERGIC TRANSMISSION; DEGENERATIVE DISEASE; DRUG DELIVERY SYSTEM; HUMAN; INFLAMMATION; NERVE DEGENERATION; NERVOUS SYSTEM; NEUROLOGIC DISEASE; NEUROPATHOLOGY; NONHUMAN; OLIGONUCLEOTIDE THERAPY; PRIORITY JOURNAL; ANIMAL; GENE TARGETING; GENE THERAPY; GENETICS; METABOLISM; NERVOUS SYSTEM DISEASES; PROCEDURES;

ANIMALS; BLOOD-BRAIN BARRIER; GENE TARGETING; GENETIC THERAPY; HUMANS; MICRORNAS; NERVOUS SYSTEM DISEASES;

EID: 84923856605     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612820666140314151924     Document Type: Article

References (54)

1. Flynt AS, Lai EC. Biological principles of microRNA-mediated regulation: shared themes amid diversity. Nat Rev Genet 2008; 9: 831-42.
2. Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet 2008; 9: 102-14.
3. Saba R, Schratt GM. MicroRNAs in neuronal development, function and dysfunction. Brain Res 2010; 1338: 3-13.
4. Vreugdenhil E, Berezikov E. Fine-tuning the brain: MicroRNAs. Front Neuroendocrinol 2010; 31: 128-33.
5. McNeill E, Van Vactor D. MicroRNAs shape the neuronal landscape. Neuron 2012; 75: 363-79.
6. Wibrand K, Panja D, Tiron A, et al. Differential regulation of mature and precursor microRNA expression by NMDA and metabotropic glutamate receptor activation during LTP in the adult dentate gyrus in vivo. Eur J Neurosci 2010; 31: 636-45.
7. Niwa R, Zhou F, Li C, Slack FJ. The expression of the Alzheimer's amyloid precursor protein-like gene is regulated by developmental timing microRNAs and their targets in Caenorhabditis elegans. Dev Biol 2008; 315: 418-25.
8. Patel N, Hoang D, Miller N, et al. MicroRNAs can regulate human APP levels. Mol Neurodegener 2008; 3: 10.
9. Boissonneault V, Plante I, Rivest S, Provost P. MicroRNA-298 and microRNA-328 regulate expression of mouse beta-amyloid precursor protein-converting enzyme 1. J Biol Chem 2009; 284: 1971-81.
10. Hebert SS, Horre K, Nicolai L, et al. MicroRNA regulation of Alzheimer's Amyloid precursor protein expression. Neurobiol Dis 2009; 33: 422-8.
11. Wang WX, Rajeev BW, Stromberg AJ, et al. The expression of microRNA miR-107 decreases early in Alzheimer's disease and may accelerate disease progression through regulation of beta-site amyloid precursor protein-cleaving enzyme 1. J Neurosci 2008; 28: 1213-23.
12. Ebert MS, Neilson JR, Sharp PA. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat Methods 2007; 4: 721-6.
13. Choi WY, Giraldez AJ, Schier AF. Target protectors reveal dampening and balancing of Nodal agonist and antagonist by miR-430. Science 2007; 318: 271-4.
14. Shaked I, Meerson A, Wolf Y, et al. MicroRNA-132 potentiates cholinergic anti-inflammatory signaling by targeting acetylcholinesterase. Immunity 2009; 31: 965-73.
15. Hollander JA, Im HI, Amelio AL, et al. Striatal microRNA controls cocaine intake through CREB signalling. Nature 2010; 466: 197-202.
16. Hwang do W, Son S, Jang J, et al. A brain-targeted rabies virus glycoprotein-disulfide linked PEI nanocarrier for delivery of neurogenic microRNA. Biomaterials 2011; 32: 4968-75.
17. Mishra PJ, Bertino JR. MicroRNA polymorphisms: the future of pharmacogenomics, molecular epidemiology and individualized medicine. Pharmacogenomics 2009; 10: 399-416.
18. Landi D, Gemignani F, Barale R, Landi S. A catalog of polymorphisms falling in microRNA-binding regions of cancer genes. DNA Cell Biol 2008; 27: 35-43.
19. Abelson JF, Kwan KY, O'Roak BJ, et al. Sequence variants in SLITRK1 are associated with Tourette's syndrome. Science 2005; 310: 317-20.
20. Jensen KP, Covault J, Conner TS, Tennen H, Kranzler HR, Furneaux HM. A common polymorphism in serotonin receptor 1B mRNA moderates regulation by miR-96 and associates with aggressive human behaviors. Mol Psychiatry 2009; 14: 381-9.
21. Wang G, van der Walt JM, Mayhew G, et al. Variation in the miRNA-433 binding site of FGF20 confers risk for Parkinson disease by overexpression of alpha-synuclein. Am J Hum Genet 2008; 82: 283-9.
22. Taly A, Corringer PJ, Guedin D, Lestage P, Changeux JP. Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system. Nat Rev Drug Discov 2009; 8: 733-50.
23. Wess J, Eglen RM, Gautam D. Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development. Nat Rev Drug Discov 2007; 6: 721-33.
24. Rosas-Ballina M, Olofsson PS, Ochani M, et al. Acetylcholinesynthesizing T cells relay neural signals in a vagus nerve circuit. Science 2011; 334: 98-101.
25. Soreq H, Seidman S. Acetylcholinesterase-new roles for an old actor. Nat Rev Neurosci 2001; 2: 294-302.
26. Miller BH, Zeier Z, Xi L, et al. MicroRNA-132 dysregulation in schizophrenia has implications for both neurodevelopment and adult brain function. Proc Natl Acad Sci USA 2012.
27. Beeri R, Le Novere N, Mervis R, et al. Enhanced hemicholinium binding and attenuated dendrite branching in cognitively impaired acetylcholinesterase-transgenic mice. J Neurochem 1997; 69: 2441-51.
28. Beeri R, Andres C, Lev-Lehman E, et al. Transgenic expression of human acetylcholinesterase induces progressive cognitive deterioration in mice. Curr Biol 1995; 5: 1063-71.
29. Soreq H, Wolf Y. NeurimmiRs: microRNAs in the neuroimmune interface. Trends Mole Med 2011; 17: 548-55.
30. Simon DJ, Madison JM, Conery AL, et al. The microRNA miR-1 regulates a MEF-2-dependent retrograde signal at neuromuscular junctions. Cell 2008; 133: 903-15.
31. Shaltiel G, Hanan M, Wolf Y, et al. Hippocampal microRNA-132 mediates stress-inducible cognitive deficits through its acetylcholinesterase target. Brain Structure and Function, in press.
32. Vo N, Klein ME, Varlamova O, et al. A cAMP-response element binding protein-induced microRNA regulates neuronal morphogenesis. Proc Natl Acad Sci USA 2005; 102: 16426-31.
33. Goshen I, Avital A, Kreisel T, Licht T, Segal M, Yirmiya R. Environmental enrichment restores memory functioning in mice with impaired IL-1 signaling via reinstatement of long-term potentiation and spine size enlargement. The Journal of neuroscience: the official journal of the Society for Neuroscience 2009; 29: 3395-403.
34. Shalgi R, Lieber D, Oren M, Pilpel Y. Global and local architecture of the mammalian microRNA-transcription factor regulatory network. PLoS Comput Biol 2007; 3: e131.
35. Benmoyal-Segal L, Vander T, Shifman S, et al. Acetylcholinesterase/paraoxonase interactions increase the risk of insecticide-induced Parkinson's disease. Faseb J 2005; 19: 452-4.
36. Berson A, Knobloch M, Hanan M, et al. Changes in readthrough acetylcholinesterase expression modulate amyloid-beta pathology. Brain 2008; 131: 109-19.
37. Berson A, Barbash S, Shaltiel G, et al. Cholinergic-associated loss of hnRNP-A/B in Alzheimer's disease impairs cortical splicing and cognitive function in mice. EMBO Mole Med 2012; 4: 730-42.
38. Kaufer D, Friedman A, Seidman S, Soreq H. Acute stress facilitates long-lasting changes in cholinergic gene expression. Nature, 1998; 393: 373-7.
39. Zimmerman G, Shaltiel G, Barbash S, et al. Post-traumatic anxiety associates with failure of the innate immune receptor TLR9 to evade the pro-inflammatory NFkappaB pathway. Translational Psychiatry 2012; 2: e78.
40. Ben Assayag E, Shenhar-Tsarfaty S, Ofek K, et al. Serum cholinesterase activities distinguish between stroke patients and controls and predict 12-month mortality. Mol Med 2010; 16: 278-86.
41. Golomb BA. Acetylcholinesterase inhibitors and Gulf War illnesses. Proc Natl Acad Sci USA 2008; 105: 4295-300.
42. Argov Z, McKee D, Agus S, et al. Treatment of human myasthenia gravis with oral antisense suppression of acetylcholinesterase. Neurology 2007; 69: 699-700.
43. Sklan EH, Lowenthal A, Korner M, et al. Acetylcholinesterase/paraoxonase genotype and expression predict anxiety scores in Health, Risk Factors, Exercise Training, and Genetics study. Proc Natl Acad Sci USA 2004; 101: 5512-7.
44. Tabares-Seisdedos R, Rubenstein JL. Chromosome 8p as a potential hub for developmental neuropsychiatric disorders: implications for schizophrenia, autism and cancer. Mol Psychiatry 2009; 14: 563-89.
45. Fineberg SK, Kosik KS, Davidson BL. MicroRNAs potentiate neural development. Neuron 2009; 64: 303-9.
46. Perkins DO, Jeffries CD, Jarskog LF, et al. microRNA expression in the prefrontal cortex of individuals with schizophrenia and schizoaffective disorder. Genome Biol 2007; 8: R27.
47. Cheng HY, Papp JW, Varlamova O, et al. microRNA modulation of circadian-clock period and entrainment. Neuron 2007; 54: 813-29.
48. Kocerha J, Kauppinen S, Wahlestedt C. microRNAs in CNS disorders. Neuromolecular Med 2009; 11: 162-72.
49. Stark KL, Xu B, Bagchi A, et al. Altered brain microRNA biogenesis contributes to phenotypic deficits in a 22q11-deletion mouse model. Nat Genet 2008; 40: 751-60.
50. Xu B, Roos JL, Levy S, van Rensburg EJ, Gogos JA, Karayiorgou M. Strong association of de novo copy number mutations with sporadic schizophrenia. Nat Genet 2008; 40: 880-5.
51. Meerson A, Cacheaux L, Goosens KA, Sapolsky RM, Soreq H, Kaufer D. Changes in brain MicroRNAs contribute to cholinergic stress reactions. J Mol Neurosci 2010; 40: 47-55.
52. Vereker E, O'Donnell E, Lynch MA. The inhibitory effect of interleukin-1beta on long-term potentiation is coupled with increased activity of stress-activated protein kinases. J Neurosci 2000; 20: 6811-9.
53. Hebert SS, Horre K, Nicolai L, et al. Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer's disease correlates with increased BACE1/beta-secretase expression. Proc Natl Acad Sci USA 2008; 105: 6415-20.
54. Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH. Mechanisms underlying inflammation in neurodegeneration. Cell 2010; 140: 918-34.